Evidence map›Paper›PMID 41291734›Full record

ArticleJournal of nanobiotechnology2025

Targeted suppression of CCR7/NF-κB signaling by apoptotic body-inspired colchicine nanovesicles halts atherosclerotic progression.

Qi Chen, Yuan-Shu Peng, Qian Zhong, Yu-Bo Zhang, Liu-Bing Hu, Guan-Yan Zhang, Yi-Xian Xu, Pei-Na Dong, Si Shen, Jing-Hao Wang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Qi Chen *Department of Anesthesiology, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, Guangdong, China.
Yuan-Shu Peng *Department of Materials Science and Engineering, College of Chemistry and Materials, Jinan University, Guangzhou, 511443, Guangdong, China.
Qian Zhong *Department of Anesthesiology, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, Guangdong, China.
Yu-Bo ZhangDepartment of Pharmacology, School of Medicine, and Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, Jinan University, Guangzhou, 510632, China.
Liu-Bing HuDepartment of Anesthesiology, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, Guangdong, China.
Guan-Yan ZhangDepartment of Materials Science and Engineering, College of Chemistry and Materials, Jinan University, Guangzhou, 511443, Guangdong, China.
Yi-Xian XuDepartment of Anesthesiology, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, Guangdong, China.
Pei-Na DongDepartment of Anesthesiology, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, Guangdong, China.
Si ShenMedical Imaging Center, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, Guangdong, China.
Jing-Hao WangDepartment of Pharmacy, The Guangzhou Key Laboratory of Basic and Translational Research On Chronic Diseases, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, 510630, Guangdong, China.
Zhi-Guo WangDepartment of Pharmacology, School of Pharmacy, Harbin Medical University, Harbin, 150086, Heilongjiang, China.
Huan-Tian ZhangDepartment of Bone and Joint Surgery, Key Laboratory of Regenerative Medicine of Ministry of Education, the First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, 510630, Guangdong, China. zhanghuantian@jnu.edu.cn.
Rong ZengDepartment of Materials Science and Engineering, College of Chemistry and Materials, Jinan University, Guangzhou, 511443, Guangdong, China. tzengronga@jnu.edu.cn.
Hao WangDepartment of Anesthesiology and Clinical Research Institute, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, Guangdong, China. haowang@jnu.edu.cn.

Funding

Clinical Characteristic Technology Project of Guangzhou Municipal Health Commission, China 2023P-TS28Guangdong Basic and Applied Basic Research Foundation, China 2025A1515011285"Guangdong Special Support Plan" Provincial Health Commission (Health Talent) Project, China 0720240108National Natural Science Foundation of China 32271376Science and Technology Project of Guangzhou, China 2023B03J1353
6 · The paper itself

Abstract

Atherosclerosis (AS) is a chronic inflammatory disorder characterized by foam cell formation and persistent inflammation as central pathological drivers. Although colchicine (Col) exhibits potent anti-inflammatory activities, its clinical application is limited by a narrow therapeutic window. In the present study, we developed phosphatidylserine-exposing nanovesicles (Col@PSVs) that leverage the innate phagocytic capacity of macrophage-derived foam cells by presenting surface "eat-me" signals, thereby enabling targeted immune modulation. The synergistic collaboration between Col and PSVs allows low-dose Col to retain robust anti-inflammatory efficacy while mitigating dose-dependent toxicity. Mechanistically, Col@PSVs potently suppress CCR7-mediated NF-κB signaling activation in foam cells, leading to a marked downregulation of pro-inflammatory cytokine and disruption of inflammatory cascades. In ApoE

Indexed as

AtherosclerosisColchicineNF-kappa BReceptors, CCR7Signal TransductionAnimalsAnti-Inflammatory AgentsApoptosisDisease ProgressionFoam CellsHumansMaleMiceMice, Inbred C57BLPhosphatidylserinesAnti-Inflammatory AgentsCcr7 protein, mouseColchicineNF-kappa BPhosphatidylserinesReceptors, CCR7Apoptotic cell-derived microvesiclesAtherosclerosisChronic inflammationColchicine

Identifiers

PMID41291734
PMCPMC12751986

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.